Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GBTNASDAQ:ITCINASDAQ:SMMTNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsITCIIntra-Cellular Therapies$131.87$131.87$66.26▼$131.98$14.05B0.691.56 million shsN/ASMMTSummit Therapeutics$20.59+4.4%$23.43$6.78▼$36.91$15.29B-1.063.62 million shs3.91 million shsUTHRUnited Therapeutics$325.82+1.9%$301.06$266.98▼$417.82$14.42B0.57439,500 shs317,040 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%ITCIIntra-Cellular Therapies0.00%0.00%0.00%+0.48%+94.47%SMMTSummit Therapeutics+4.36%+10.34%-15.07%+15.80%+156.09%UTHRUnited Therapeutics+1.91%+3.00%+6.14%+3.14%+17.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGBTGlobal Blood Therapeutics0.3394 of 5 stars0.00.00.04.00.60.00.6ITCIIntra-Cellular Therapies0.8911 of 5 stars1.10.00.04.50.01.70.6SMMTSummit Therapeutics2.9267 of 5 stars4.53.00.00.01.91.70.0UTHRUnited Therapeutics4.846 of 5 stars3.32.00.04.62.83.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBTGlobal Blood Therapeutics 0.00N/AN/AN/AITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideSMMTSummit Therapeutics 3.09Buy$37.4081.64% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$393.0020.62% UpsideCurrent Analyst Ratings BreakdownLatest GBT, SMMT, ITCI, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.006/2/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$405.005/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$425.00 ➝ $425.005/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.005/1/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$346.00 ➝ $348.005/1/2025UTHRUnited TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$355.00 ➝ $350.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.004/28/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.004/25/2025SMMTSummit TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$31.00 ➝ $44.004/25/2025UTHRUnited TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$395.00 ➝ $314.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBTGlobal Blood Therapeutics$194.75M23.73N/AN/A$3.05 per share22.46ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44SMMTSummit Therapeutics$700K21,844.99N/AN/A$0.11 per share187.18UTHRUnited Therapeutics$2.99B4.91$19.59 per share16.63$127.35 per share2.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBTGlobal Blood Therapeutics-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ASMMTSummit Therapeutics-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)UTHRUnited Therapeutics$984.80M$25.0614.3111.850.9740.31%19.22%16.15%7/30/2025 (Estimated)Latest GBT, SMMT, ITCI, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBTGlobal Blood Therapeutics4.926.886.17ITCIIntra-Cellular TherapiesN/A7.667.51SMMTSummit TherapeuticsN/A8.318.31UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBTGlobal Blood TherapeuticsN/AITCIIntra-Cellular Therapies92.33%SMMTSummit Therapeutics4.61%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipGBTGlobal Blood Therapeutics4.90%ITCIIntra-Cellular Therapies2.60%SMMTSummit Therapeutics84.90%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGBTGlobal Blood Therapeutics45767.48 million64.17 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableSMMTSummit Therapeutics110742.67 million86.28 millionOptionableUTHRUnited Therapeutics98045.11 million39.33 millionOptionableGBT, SMMT, ITCI, and UTHR HeadlinesRecent News About These CompaniesHennion & Walsh Asset Management Inc. Purchases 1,970 Shares of United Therapeutics Co. (NASDAQ:UTHR)June 7 at 4:33 AM | marketbeat.comUnited Therapeutics: A Cheap But Complicated TaleJune 6 at 2:39 PM | seekingalpha.comLeerink Partnrs Brokers Increase Earnings Estimates for UTHRJune 6 at 6:28 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Rhumbline AdvisersJune 5 at 4:42 AM | marketbeat.comCorcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?June 4 at 4:48 PM | finance.yahoo.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Veracity Capital LLCJune 4 at 7:51 AM | marketbeat.comUnigestion Holding SA Makes New $2.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)June 3, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Milestone Asset Management LLCJune 3, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by GAMMA Investing LLCJune 3, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of United Therapeutics (UTHR) with Overweight RecommendationJune 2, 2025 | msn.comUnited Therapeutics (NASDAQ:UTHR) Coverage Initiated at Cantor FitzgeraldJune 2, 2025 | marketbeat.comUnited Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock NewsJune 2, 2025 | gurufocus.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,476,770.00 in StockJune 2, 2025 | americanbankingnews.comAnalysts Set United Therapeutics Co. (NASDAQ:UTHR) PT at $392.00June 1, 2025 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 SharesMay 31, 2025 | marketbeat.comSummit Global Investments Has $4.33 Million Position in United Therapeutics Co. (NASDAQ:UTHR)May 31, 2025 | marketbeat.comCalifornia State Teachers Retirement System Sells 6,861 Shares of United Therapeutics Co. (NASDAQ:UTHR)May 31, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes $16.51 Million Position in United Therapeutics Co. (NASDAQ:UTHR)May 31, 2025 | marketbeat.comWhy Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?May 30, 2025 | zacks.com13,541 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Lansforsakringar Fondforvaltning AB publMay 30, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Sells 1,090 Shares of United Therapeutics Co. (NASDAQ:UTHR)May 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGBT, SMMT, ITCI, and UTHR Company DescriptionsGlobal Blood Therapeutics NASDAQ:GBTGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Summit Therapeutics NASDAQ:SMMT$20.59 +0.86 (+4.36%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$20.72 +0.14 (+0.66%) As of 06/6/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.United Therapeutics NASDAQ:UTHR$325.82 +6.11 (+1.91%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$325.66 -0.16 (-0.05%) As of 06/6/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
